Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spencer Shaw

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
British Journal of Nursing (Mark Allen Publishing)|January 19, 2010
Managing adverse events associated with sorafenib in renal cell carcinomaKim Edmonds, Andrea Spencer-Shaw
Clinical Radiology|March 26, 2004
To clot or not to clot? That is the question in central venous cathetersA Cadman, J A L Lawrance, L Fitzsimmons, et al.
Journal of Clinical Gastroenterology|November 14, 2015
Safety of Propofol Used as a Rescue Agent During ColonoscopyFrancis C Okeke, Spencer Shaw, Kristel K Hunt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancerAlaaeldin Shablak, Kanwal Sikand, Jonathan H Shanks, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|June 7, 2011
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task groupKim Edmonds, Diana Hull, Andrea Spencer-Shaw, et al.
Journal for Immunotherapy of Cancer|October 26, 2016
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcomeS Chow, V Galvis, M Pillai, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
British Journal of Nursing (Mark Allen Publishing)|January 19, 2010
Managing adverse events associated with sorafenib in renal cell carcinomaKim Edmonds, Andrea Spencer-Shaw
Clinical Radiology|March 26, 2004
To clot or not to clot? That is the question in central venous cathetersA Cadman, J A L Lawrance, L Fitzsimmons, et al.
Journal of Clinical Gastroenterology|November 14, 2015
Safety of Propofol Used as a Rescue Agent During ColonoscopyFrancis C Okeke, Spencer Shaw, Kristel K Hunt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancerAlaaeldin Shablak, Kanwal Sikand, Jonathan H Shanks, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|June 7, 2011
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task groupKim Edmonds, Diana Hull, Andrea Spencer-Shaw, et al.
Journal for Immunotherapy of Cancer|October 26, 2016
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcomeS Chow, V Galvis, M Pillai, et al.
Pageof 1